Menin inhibitors in acute leukemia
搜索文档
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Seeking Alpha· 2025-12-09 06:17
PresentationAt this time, I would like to turn the call over to Troy Wilson, President and CEO of Kura Oncology. Dr. Wilson. Please go ahead.Good day, everyone. My name is Abigail, and I will be your conference operator today. At this time, I would like to welcome you to the Kura ASH 2025 Update Call. [Operator Instructions]Troy WilsonChairman, CEO & President Thank you, Abigail, and good afternoon, everyone. Welcome to our ASH 2025 analyst and investor event. This is -- this has been a big day, and it's be ...